ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Clinical trials for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for tough kidney diseases
Disease control OngoingThis study tests a new drug called povetacicept in adults with certain autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The goal is to see if the drug is safe and can help control the disease. Participants receive the drug every 4 weeks for at least 6 mo…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1, PHASE2 • Sponsor: Alpine Immune Sciences, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
Kidney failure patients may ditch immune drugs in landmark trial
Disease control OngoingThis study looks at whether people with ANCA vasculitis who have reached end-stage kidney disease can safely stop taking immunosuppressive medications. The goal is to see if stopping these drugs lowers the risk of serious infections and other side effects without causing dangerou…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE3 • Sponsor: Centre Hospitalier Departemental Vendee • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Engineered immune cells take on lupus and vasculitis in early trial
Disease control OngoingThis early-phase study tests a new treatment called SC291 for people with severe lupus or vasculitis that hasn't responded to standard therapies. SC291 uses donor immune cells engineered to target and destroy faulty immune cells driving the disease. The main goal is to check safe…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC